Translational research models and novel adjunctive therapies for neuroAIDS

Research output: Contribution to journalArticle

Abstract

The goal of this component of the meeting was to discuss novel therapeutics that attenuate inflammatory pathways, enhance drug delivery into the brain and/or bypass the blood-brain barrier (BBB). Presentations included discussions of (i) antiretroviral drugs packaged into nanoparticles by Howard Gendelman, (ii) how to engage the nasal epithelium and its closely associated neural fibers as a route for drug entry to the brain, by William H. Frey and Lynn Pulliam, and (iii) antioxidant gene delivery to neurons using vector systems that can protect neurons against HIV-associated toxicity, by David Strayer. The session was capped by active discourse among leaders in the field of adjunctive therapies in a broad range of scientific disciplines.

Original languageEnglish (US)
Pages (from-to)14-19
Number of pages6
JournalJournal of Neuroimmune Pharmacology
Volume2
Issue number1
DOIs
StatePublished - Mar 1 2007

Keywords

  • Anti-inflammatory
  • Antioxidants
  • Blood-brain barrier
  • Gene delivery
  • HIV-1 proteins
  • Lentiviruses
  • Microglia
  • Mononuclear phagocytes
  • NeuroAIDS therapeutics

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Immunology and Allergy
  • Immunology
  • Pharmacology

Fingerprint Dive into the research topics of 'Translational research models and novel adjunctive therapies for neuroAIDS'. Together they form a unique fingerprint.

  • Cite this